IMpassion130: Atezolizumab and nab-paclitaxel in triple-negative breast cancer

Bookmark and Share
Published: 22 Sep 2020
Views: 413
Prof Leisha Emens - University of Pittsburgh, Pittsburgh, USA

Prof Leisha Emens spoke to ecancer online about the IMpassion130 trial presented at ESMO 2020.

The IMpassion130 trial is an exploratory analysis of atezolizumab and nab-paclitaxel for patients with triple-negative breast cancer.

She outlined the reasoning and background of the trial before outlining some of the results thus far.

Pro Emens also discussed toxicities and the next steps for IMpassion130.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.